Abstract 309P
Background
The American College of radiology proposed BI-RADS lexicon lacks defined rules which direct conversion of specific imaging features into a diagnostic category, results in a discrepancy of reporting. This study compares results from multilayer Perceptron neural network and a classification tree.
Methods
A total of 316 lesions with successive histological verification (221 malignant, 95 benign) were investigated. Six lesion criteria's were assessed by 2 readers in consensus. Classification analysis was performed using the chi-squared automatic interaction detection (CHAID) method. Results include the probability for malignancy for every descriptor combination in the classification tree. Simultaneously a multilayer Perceptron neural network was developed by using SPSS software.
Results
A classification tree incorporating 6 lesion descriptors with a depth of 4 ramifications (1- ADC values; 2 -root sign; 3- enhancement pattern; 4 - oedema) was calculated. Of all 316 lesions, 38 (40 %) and 212 (95.9 %) could be classified as benign and malignant with an accuracy above 95 %, respectively. Overall diagnostic accuracy was 79.1 %. The multilayer perceptron network segregated the lesions into training and testing sets in a ratio of 7:3. With a hyperbolic tangent activation function, there were six units of hidden layer and the model show a 20% and 17% incorrect predictions in the training in the testing sets. The diagnostic accuracy of malignant and benign lesions was 92% and 52 % in both the training and testing sets. The area under the curve of the ROC was .855. The order of importance of synaptic weights calculated from the model were ADC ( 0.257), Internal enhancement (0.233), ROOT SIGN (0.175), Margins (0.138), Curve type (0.138), edema (0.038) and mass / non mass (0.021).
Conclusions
The classification algorithm correctly classified 95 % malignant lesions with accuracy above 95 %. The neural network model showed good results on internal validation and revealed ADC to be the most significant parameter with the least importance to morphological classification into mass and non-mass lesions. Also, the dynamic contrast curve patterns were more significant than margins.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi Cancer Institute and Research Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session